HomeFileCoronary disease

Coronary disease

View Category

Chronic Ischemic cardiopathy

Increase in Femoral Access Complications in the Transradial Era

Original Title: The Benefits Conferred by Radial Access for Cardiac Catheterization Are Offset by a Paradoxical Increase in the...
solaci -
Learn More
Antiplatelet

ADAPT-DES: Proton Pump Inhibitors and Clopidogrel in Patients with DES

Original Title: Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients. The...
solaci -
Learn More
Chronic Ischemic cardiopathy

ABSORB III: Everolimus Eluting Bioresorbable Scaffolds for Coronary Artery Disease

Original Title: Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. Reference: Stone, M.D. for the ABSORB III Investigators. N...
solaci -
Learn More
Chronic Ischemic cardiopathy

Surgery vs. PCI in Diabetic Patients with Multivessel Disease

Original Title: Revascularization in diabetics with multivessel disease: a population-based evaluation of outcomes. Presenter: Ramanathan K. Real-world data support...
solaci -
Learn More
Chronic Ischemic cardiopathy

PROMISE Subanalysis: Potential Benefits of CT Angiography over Functional Studies in Patients with Symptoms Suggesting CAD

Original Title: Outcomes of anatomical versus functional testing for coronary artery disease. Presenter: Douglas PS. Early this year, the...
solaci -
Learn More
Chronic Ischemic cardiopathy

IVUS-XPL: IVUS superior to angiography for guiding DES implantation in long lesions

Original Title: Effect of intravascular ultrasound-guided vs angiography-guided everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial. Presenter: Hong...
solaci -
Learn More
Coronary disease

Polymer Free Drug Coated Stent in High Bleeding Risk Patients with Only One Month DAPT

Original Title: Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk Reference: Philip Urban et al. N...
solaci -
Learn More
Drug-eluting stents

OPTIDUAL: Dual Antiaggregation Not Beneficial after 12 Months.

Extending dual antiaggregation therapy (DAT) from 12 to 48 months appears not to offer extra protection after...
solaci -
Learn More